# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
These ten large-cap stocks were top performers last week. Are they a part of your portfolio?
Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...
Barclays analyst Etzer Darout initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underweight rating and announce...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a ...